The Supreme Court is expected to hear oral arguments in Amgen Inc. v. Connecticut Retirement Plans and Trust Funds, in which the big biotech is appealing a decision from the Court of Appeals for the Ninth Circuit that upheld a federal district court's refusal to hear evidence rebutting fraud-on-the-market claims involving erythropoietins before it certified a class in the shareholder lawsuit.